Menu
Recruiting NCT05389930

Cannabis' Impact on Alcohol Consumption

Phase II Interventional Alcohol Drinking Cannabis Use Cannabis Alcohol Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol.
Who it may be relevant to
Registry conditions: Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder. Basic parameters: 21 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods

Overview

This study employs a repeated measures experimental design to examine the effect of THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consumed. Cannabis will be administered simultaneously with an alcohol-priming dose or alcohol placebo. The study will enroll up to 350 nontreatment-seeking heavy episodic alcohol drinkers who use cannabis weekly.

Detailed description

This study employs a repeated measures experimental design to examine the effect of THC-dominant (9.53% THC and 0.09% CBD) dose of cannabis and CBD-dominant (0.35% THC and 11.27% CBD) dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consumed. Cannabis will be administered simultaneously with an alcohol-priming dose or alcohol placebo. The study will enroll up to 350 nontreatment-seeking heavy episodic alcohol drinkers who use cannabis weekly to obtain the final sample of 200 with complete data. Participants will be tested at a baseline session, during three experimental sessions, and then during a subsequent 4-week period in the natural environment using a smart-phone application. Findings have important implications for cannabis regulatory science and alcohol use disorder treatment by addressing the relative impact of specific cannabinoids as well as contextual risk in cannabis-alcohol co-use.

Interventions

  • Drug THC-dominant cannabis
    Smoked cannabis with 9.53% THC and 0.09% CBD
  • Drug CBD-dominant cannabis
    Smoked cannabis with 0.35% THC and 11.27% CBD
  • Drug Cannabis placebo
    Smoked placebo cannabis plant material
  • Drug Alcohol
    Drink containing 0.3 g/kg of alcohol
  • Drug Alcohol placebo
    Placebo beverage contains only juice and a negligible trace of alcohol for masking

Primary outcome measures

  • ml of alcohol consumed [Time frame: post-smoking during two-hours of the alcohol choice task]

Eligibility criteria

Inclusion criteria

  • Age 21 to 50
  • English-speaking
  • cannabis smoking in past two months
  • heavy drinking in past two months
  • in good physical health and weighing < 250 lbs
  • zero breath alcohol at each visit

Exclusion criteria

  • positive pregnancy test
  • nursing
  • positive urine toxicology screen for drugs other than cannabis
  • interest to quit or receive treatment for cannabis or alcohol use

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Factorial
Masking
Double blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • Brown University — Providence

Identifiers

NCT: NCT05389930 · 2022003195 · R01AA029711

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗